5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 20.13▲ | 20.35▼ | 20.41▼ | 20.62▼ | 20.58▼ |
MA10 | 20.20▼ | 20.54▼ | 20.71▼ | 20.42▼ | 20.02▲ |
MA20 | 20.34▼ | 20.78▼ | 20.68▼ | 20.22▼ | 20.08▲ |
MA50 | 20.55▼ | 20.74▼ | 20.70▼ | 19.37▲ | 26.78▼ |
MA100 | 20.75▼ | 20.64▼ | 20.18▼ | 20.38▼ | 30.81▼ |
MA200 | 20.81▼ | 20.18▼ | 19.93▲ | 25.15▼ | 33.62▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.015▼ | -0.100▼ | -0.104▼ | 0.029▲ | 0.648▲ |
RSI | 36.114▼ | 39.527▼ | 44.206▼ | 50.317▲ | 44.211▼ |
STOCH | 18.574▼ | 7.854▼ | 11.274▼ | 49.259 | 73.516 |
WILL %R | -78.723▼ | -92.982▼ | -97.462▼ | -70.620 | -40.187 |
CCI | -57.786 | -143.471▼ | -124.719▼ | 25.881 | 58.219 |
Saturday, June 14, 2025 07:50 AM
Celldex Therapeutics has announced promising results from its Phase 2 clinical trial of barzolvolimab, a treatment for chronic spontaneous urticaria (CSU), demonstrating significant improvements ...
|
Saturday, June 14, 2025 12:48 AM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic ...
|
Friday, June 13, 2025 11:17 AM
US immunology specialist Celldex was trading 5% higher midday Friday, following on from 10% gains on Thursday.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 21.21 | 21.35 | 20.00 | 20.16 | 963,997 |
13/06/25 | 20.21 | 24.03 | 20.00 | 21.26 | 2,820,512 |
12/06/25 | 20.13 | 21.05 | 19.655 | 20.35 | 1,957,398 |
11/06/25 | 21.05 | 21.32 | 20.40 | 20.42 | 904,291 |
10/06/25 | 20.92 | 21.72 | 20.92 | 20.92 | 891,581 |
09/06/25 | 21.83 | 21.83 | 20.055 | 20.71 | 851,207 |
06/06/25 | 19.87 | 21.43 | 19.87 | 21.35 | 852,593 |
05/06/25 | 19.56 | 19.765 | 19.245 | 19.53 | 667,715 |
04/06/25 | 19.68 | 20.03 | 19.31 | 19.67 | 754,012 |
03/06/25 | 19.92 | 20.56 | 19.47 | 19.87 | 2,485,387 |
|
|
||||
|
|
||||
|
|